New Multinational Multicenter, Hard-Endpoint Clinical Study Results Announced, ReDS™ Pro Reduces 30-Day Death and Readmission Rates in 91% of Heart Failure Patients - JACC Reissue

2024-03-25

Save time! Get the best deal

 

Please fill in the following information, we will contact you as soon as possible after receiving the information, thank you for your message!

* Name
Phone
* Email
Company
* Message